Lower-dose alteplase could be a game-changer for acute stroke
11th May 2016
The controversial clot busting drug rtPA (alteplase) has been given the green light by Australian scientists who have found lowering the dose is effective.
Results from a trial of more than 3000 patients in 100 hospitals worldwide show a modified dosage of rtPA reduces the risk of intracerebral haemorrhage and improves survival rates.
The researchers from the St George Institute for Global Health say they